Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous Lumbar Plexus Block in Hip Fracture
NCT01961895Phase 4Completed
- Sponsor
- Pontificia Universidad Católica de Chile
- Start
- May 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bupivacaine hydrochloride 0.75% injection in Myocardial ischemia (MI) and pain (2 arms), sponsored by Pontificia Universidad Católica de Chile. Primary endpoint: Reduction of ischemic events per subject at 3 days. Started May 2010; status: completed.
02
Drugs
bupivacaine hydrochloride 0.75% injection
03
Conditions
Myocardial ischemia (MI)pain
Beyond the preview
Go deeper on NCT01961895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961895.